Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.2312
Abstract: Key Points Question Is it possible to predict short-term treatment response to tumor necrosis factor inhibitors (TNFis) accurately in patients with active ankylosing spondylitis (AS)? Findings In a cohort study of individual participant data from… read more here.
Keywords: necrosis factor; response tumor; tumor necrosis; factor inhibitors ... See more keywords
Detection and Measurement of Factor Inhibitors.
Sign Up to like & getrecommendations! Published in 2017 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-7196-1_23
Abstract: Specific coagulation factor inhibitors, most notably to coagulation factor VIII, can develop in patients with hemophilia after exposure to replacement factor or as an acquired (autoimmune) event. Such inhibitors can be detected by a combination… read more here.
Keywords: measurement factor; factor inhibitors; detection measurement; biology ... See more keywords
Factor Xa inhibitors: critical considerations for clinical development and testing
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-021-02455-x
Abstract: The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor… read more here.
Keywords: factor inhibitors; critical considerations; inhibitors critical; considerations clinical ... See more keywords
A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Hematology"
DOI: 10.1007/s12185-018-2453-z
Abstract: Acquired coagulation factor inhibitors are rare. Among them, coagulation factor V (FV) inhibitor is particularly uncommon and presents with variable clinical manifestations. Certain acquired FV inhibitor patients have only mild bleeding or, in select cases,… read more here.
Keywords: factor inhibitors; diagnosis; time; normotest hepaplastintest ... See more keywords
Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-021-00488-4
Abstract: During the several decades of clinical use of warfarin in patients with atrial fibrillation (AF), prescribers have been accustomed to the possibility of modulating the intensity of oral anticoagulation therapy (OAT). While the international normalized… read more here.
Keywords: factor inhibitors; modulating intensity; safety; intensity oral ... See more keywords
Low risk of traumatic intracranial hematoma expansion with factor Xa inhibitors without andexanet reversal.
Sign Up to like & getrecommendations! Published in 2020 at "World neurosurgery"
DOI: 10.1016/j.wneu.2020.06.069
Abstract: BACKGROUND Andexanet alfa, a novel anticoagulation reversal agent for Factor Xa inhibitors, was recently approved. Traumatic intracranial hemorrhage presents a prime target for this drug. The ANNEXA-4 study established the efficacy of andexanet alfa in… read more here.
Keywords: reversal; factor inhibitors; andexanet; hemorrhage ... See more keywords
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and Haemostasis"
DOI: 10.1055/a-2043-0346
Abstract: BACKGROUND Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes. METHODS We performed a systematic review and meta-analysis of RCT… read more here.
Keywords: efficacy; factor inhibitors; fxi inhibitors; meta analysis ... See more keywords
Managing patients on direct factor Xa inhibitors with rapid thrombelastography.
Sign Up to like & getrecommendations! Published in 2021 at "Scandinavian journal of clinical and laboratory investigation"
DOI: 10.1080/00365513.2021.2003855
Abstract: The use of direct factor Xa inhibitors rivaroxaban and apixaban (XABANs) has rapidly increased; however, there is no validated test available to monitor the effect on hemostasis. This study aims to assess how hemostatic management… read more here.
Keywords: act 120; factor inhibitors; xaban patients; direct factor ... See more keywords
A review of emerging factor XI inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2023.2192923
Abstract: ABSTRACT Introduction Whilst the introduction of direct oral anticoagulants (DOACs) has improved the prevention of thromboembolic events, there is still a need for safer anticoagulants. This is particularly so, for specific populations of patients, such… read more here.
Keywords: review emerging; fxi inhibition; factor; emerging factor ... See more keywords
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2022.2020648
Abstract: ABSTRACT Background The molecular signature response classifier (MSRC) is a blood-based precision medicine test that predicts nonresponders to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA) so that patients with a molecular signature of… read more here.
Keywords: factor inhibitors; rheumatoid arthritis; treatment; selection ... See more keywords
Factor XI inhibitors: cardiovascular perspectives.
Sign Up to like & getrecommendations! Published in 2022 at "European heart journal"
DOI: 10.1093/eurheartj/ehac464
Abstract: Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not completely effective, and concerns about the risk of bleeding continue to limit their uptake. Animal studies and experience from patients with genetic… read more here.
Keywords: factor inhibitors; factor; inhibitors cardiovascular; cardiovascular perspectives ... See more keywords